Human platelet aggregation tests in vitro. Effects of dilazep

Area of Science:

• Pharmacology
• Hematology
• Cardiovascular Medicine

Background:

• Dilazep (Cormelian) is a coronaroactive drug with potential effects on hemostasis.
• Understanding its impact on blood clotting and platelet function is crucial for its clinical application.

Purpose of the Study:

• To investigate the in vitro effects of dilazep on various hemostasis parameters in human plasma.
• To determine the specific actions of dilazep on platelet aggregation, availability of platelet factor 3 (PF3), and clot retraction.

Main Methods:

• In vitro study of dilazep on human plasma.
• Assessment of hemostasis parameters including ADP, adrenaline, and collagen-induced platelet aggregation.
• Evaluation of platelet factor 3 (PF3) availability and clot retraction.
• Analysis of coagulation tests and lysis time of diluted whole blood.

Main Results:

• Dilazep significantly inhibited ADP, adrenaline, and collagen-induced platelet aggregation.
• The drug demonstrated inhibition of platelet factor 3 (PF3) availability and ADP-reptilase-induced clot retraction.
• Coagulation tests and the lysis time of diluted whole blood remained unaffected by dilazep.

Conclusions:

• Dilazep exhibits clear antiplatelet activity in vitro.
• The drug's effects are specific to platelet function, with no observed impact on coagulation or fibrinolysis.
• These findings highlight dilazep's potential as an antiplatelet agent in cardiovascular therapy.